IXinity: Withdrawal of the marketing authorisation application


On 13 June 2013, Cangene Europe Ltd. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for IXinity, for the treatment and prevention of bleeding in patients with haemophilia B.

  • List item

    Questions and answers on the withdrawal of the marketing authorisation application for IXinity (PDF/73.5 KB)


    First published: 28/06/2013
    Last updated: 28/06/2013

  • Key facts

    Product number
    Active substance
    • Trenonacog alfa
    • Trenonacog alfa
    Date of withdrawal
    Company making the application
    Cangene Europe Limited
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating